US 12,440,510 B2
Use of chondroitin sulfate for relieving ocular pain
Richard L. Lindstrom, Wayzata, MN (US); Kamran Hosseini, Pleasanton, CA (US); and Lyle Bowman, Pleasanton, CA (US)
Assigned to Surface Ophthalmics, Inc., Pleasanton, CA (US)
Filed by SURFACE OPHTHALMICS, INC., Pleasanton, CA (US)
Filed on May 3, 2024, as Appl. No. 18/654,457.
Application 18/654,457 is a continuation in part of application No. 18/555,982, granted, now 12,310,981, previously published as PCT/US2022/027177, filed on May 1, 2022.
Claims priority of provisional application 63/186,747, filed on May 10, 2021.
Prior Publication US 2024/0285675 A1, Aug. 29, 2024
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/737 (2006.01); A61K 9/00 (2006.01)
CPC A61K 31/737 (2013.01) [A61K 9/0048 (2013.01)] 10 Claims
 
1. A method of treating ocular pain or discomfort, the method comprising: topically administering eye drops to an eye of a subject suffering from ocular pain or discomfort from ocular injury or an ocular surface disease, the eye drops comprising a therapeutically effective amount of chondroitin sulfate at a concentration from 0.1% to 2.5% wt/wt, wherein the eye drops have a viscosity about equal to water.